Quite refreshing well-written experimental paper leaving promises of artificial organoids.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
In Situ Expansion, Differentiation and Electromechanical Coupling of Human Cardiac Muscle in a 3D Bioprinted, Chambered Organoid
April 2, 2020
December 19, 2019
Donor lungs undergoing EVLP were more injured, but long-term outcomes of transplant were similar between EVLP and non-EVLP lungs, including the incidence of graft dysfunction and survival.
Evaluation of the INSPIRE Trial and Its Implications for Lung Transplantation With Normothermic Portable Ex Vivo Lung Perfusion
October 30, 2019
A balanced appraisal of last year's manuscript from the Lancet Group on a relatively novel portable Organ Care System for donor lungs. The analysis of the technical complications, especially organ damage from overenthusiastic revving of the pump, is particularly sobering.
October 9, 2019
Ex vivo lung perfusion was used in 25% of transplanted lungs in the Toronto program since 2008. This resulted in an increase in the number of transplanted patients without any degradation of long-term outcomes, including survival and freedom from chronic dysfunction.
August 4, 2019
The Throacic Surgery Residents Association (TSRA) Decision Algorithms in Cardiothoracic Surgery is a 100-chapter compendium with an individual algorithm for clinical decisions spanning the entire scope of cardiothoracic surgery.
June 8, 2019
June 4, 2019
Left ventricular ejection fraction was not a predictor of outcomes after heart transplant, and was normal in all recipients at 1 year posttransplant. The reliance on generic transthoracic echocardiography for donor assessment may well be the Achilles heel of this retrospective case study.
May 21, 2019
The authors utilized a retrospective review of the UNOS database from 2007-2014 to evaluate the impact of donor sequence number (DSN) on outcomes.
May 3, 2019
The US FDA approved the Xvivo device for maintaining or resuscitating donor lungs prior to transplant. Interesting very high survival is reported in the control group at one year.
April 28, 2019
The authors of this single-center open-label pilot trial evaluated the intermediate-term outcomes of patients undergoing either heart (n=8) or lung (n=36) transplantation from donors that had evidence of active hepatitis C virus (HCV) infection. All patients underwent treatment of HCV antiviral treatment for 4 weeks after transplantation.